M&A TRANSACTION · 2022
Inform Diagnostics acquired by Fulgent Genetics, Inc.
$138.9M· 9.9x EBITDA
Target
Inform Diagnostics
Acquirer
Fulgent Genetics, Inc.
Strategic buyer
Disclosed financials at time of acquisition
Revenue
—
EBITDA
$14.1M
Deal Value
$138.9M
EV/EBITDA
9.9x
Context
This $138.9M acquisition of Inform Diagnostics by Fulgent Genetics, Inc. sits in the laboratory services sub-vertical. The 9.9x EBITDA multiple paid in 2022 can be compared against the population median for laboratory services transactions of similar size on our Laboratory Services valuation hub. Fulgent Genetics, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price laboratory services businesses on our Laboratory Services strategic buyer-pool page.
Source
Data sourced from SEC filings and press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology
Value your own laboratory services
Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.
Compare your business to the Inform Diagnostics acquisition.